Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by New York University School of Medicine.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Novartis Pharmaceuticals
The Children's Tumor Foundation
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01419639
First received: August 17, 2011
Last updated: November 9, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2013
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)